Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall Street ends lower as tech shares slip
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Taiwan prosecutors detain Super Micro employees over chip exports
Delcath Systems (DCTH) PT Raised to $20 at BTIG
August 6, 2024 4:57 AM EDTBTIG analyst Marie Thibault raised the price target on Delcath Systems (NASDAQ: DCTH) to $20.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "The U.S. commercial launch is ramping quicker than we initially expected with Delcath Systems reporting total Q2 sales of $7.8M, including $6.6M from Hepzato and $1.2M from OUS Chemosat sales. This was well above consensus of $5.2M. Seven treating centers were active in the quarter, performing what we estimate were 36 combined... More
